Columvi (glofitamab)
Research Synopsis
- Columvi (glofitamab) is a bispecific antibody designed to target CD20 on B cells and CD3 on T cells, showing significant potential in treating relapsed or refractory B-cell lymphoproliferative disorders, such as mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL).* -
- Recent studies have reported an impressive overall response rate of approximately 53.8% for patients with heavily pretreated B-cell non-Hodgkin lymphoma (NHL), indicating its efficacy in challenging cases.* -
- Glofitamab has demonstrated durable complete remissions, with one phase I study showing 36.8% of patients achieving complete responses after treatment, even in those with aggressive lymphoma subtypes.* -
- Treatment responses have been noted to persist, and in some studies, over 78% of complete responses remained ongoing for up to 12 months following treatment.* -
- However, the treatment has potential side effects, with a significant portion of patients experiencing cytokine release syndrome, which necessitates careful management.* -
- Research has identified that approximately 62% of treated patients encountered significant adverse events, indicating the need for monitoring and supportive care.* -
- Challenges persist regarding treatment after glofitamab, particularly concerning relapses related to the loss of essential markers like CD20, indicating a potential unmet medical need for further therapeutic options.* -
- The recent advancements, including the development of a novel dosing method for glofitamab, showcase the continued innovation in optimizing this therapy for maximum patient benefit.* -
- Glofitamab’s unique configuration potentially enhances its pharmacokinetics and targeting capabilities, differentiating it from existing therapies and suggesting a promising avenue for future oncology treatments.* -
- Extensive ongoing clinical trials continue to evaluate glofitamab's efficacy, complementary use with other therapies, and its place in treatment sequences for patients with complex relapsed and refractory B-cell malignancies.*
Columvi (glofitamab)
Advancing drug development in pediatric oncology, a focus on cancer biology and targeted therapies: iMATRIX platform.
London, UK
2 hours ago
1 Received
- Recent advancements in pediatric oncology drug development have led to innovative therapies and clinical trial approaches, though new drug approvals remain slow.
- Regulatory changes in the US and Europe have increased the urgency for faster drug development tailored to pediatric patients with cancer.
- The iMATRIX platform showcases a new trial framework that studies multiple drugs for various pediatric tumor types simultaneously, with six studies currently conducted or planned to test different treatment options.
$100 - $150
Hourly Rate
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study.
London, UK
2 hours ago
1 Received
- Some patients with a type of cancer called mantle cell lymphoma (MCL) don't have good treatment options if their cancer comes back.
- A study tested a new medicine called glofitamab, which was given after patients received another medicine to help reduce side effects.
- The results showed that many patients got better from the treatment, and while some had side effects, these were manageable with proper care.
$100 - $150
Hourly Rate
Relapse after glofitamab, a novel unmet medical need with high rates of CD20 loss.
London, UK
2 hours ago
1 Received
- The treatment outlook for a type of cancer called r/r DLBCL has gotten much better because of new therapies that activate T-cells.
- These therapies, like chimeric antigen receptor T-cell therapy and bispecific antibodies, help some patients, but there are still new challenges to face.
- A recent study found that some patients who don’t have a certain marker (CD20) after treatment with a drug called glofitamab need new treatments since their current options are limited.
$100 - $150
Hourly Rate
Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model.
London, UK
2 hours ago
1 Received
- Diffuse large B cell lymphomas (DLBCL) are a common and complex form of Non Hodgkin Lymphoma, with a significant number of patients experiencing relapse despite treatment, highlighting the need for better therapies.
- CD20-TCB, a novel bi-specific antibody that targets T cells to attack DLBCL, shows promise by quickly forming stable interactions between T cells and tumor cells, which enhances anti-tumor effects.
- Research using advanced imaging techniques demonstrated that the effectiveness of CD20-TCB is linked to its ability to induce rapid synapse formation and recruit T cells from the body, and this process can be partially disrupted by blocking certain immune signaling pathways.
$100 - $150
Hourly Rate
A PHP Error was encountered
Severity: 8192
Message: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated
Filename: helpers/my_audit_helper.php
Line Number: 8900
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 8900
Function: str_replace
File: /var/www/html/application/views/drugView.php
Line: 168
Function: formatAIDetailSummary
File: /var/www/html/application/views/includes/template.php
Line: 3
Function: view
File: /var/www/html/application/controllers/Drug.php
Line: 246
Function: view
File: /var/www/html/index.php
Line: 316
Function: require_once
Engaging results with glofitamab.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
London, UK
2 hours ago
1 Received
- Glofitamab is a bispecific antibody targeting CD20 on B cells and CD3 on T cells, evaluated in a phase I study for patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) after pretreatment with obinutuzumab to lower toxicity.
- The study involved 171 heavily pretreated patients, most of whom had aggressive lymphoma subtypes, and focused on safety, pharmacokinetics, and dosage limits of glofitamab.
- Results showed a 53.8% overall response rate with 36.8% achieving complete response; responses were durable, with manageable side effects, including cytokine release syndrome.
$100 - $150
Hourly Rate
Bispecific antibodies for the treatment of lymphomas: Promises and challenges.
London, UK
2 hours ago
1 Received
- Bispecific antibodies, recognized over 35 years ago, target malignant cells by linking T-cell receptor-specific antibodies with tumor-targeting antibodies to enhance T cell-mediated cytotoxicity.
- These antibodies engage T cells to attack tumor cells, bypassing the need for MHC-mediated presentation and directly focusing on cells with the target antigen.
- The review highlights early phase 1 trials of bispecific antibodies for treating relapsed B-cell lymphomas, particularly those targeting CD20 while activating T cells through CD3.
$100 - $150
Hourly Rate
Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins.
London, UK
2 hours ago
1 Received
- Bispecific antibodies, which can target two substances simultaneously, have gained significant attention, especially with the introduction of CrossMab technology in 2011, which improves the design of these antibodies.
- Over the past decade, CrossMab technology has matured, leading to nearly 20 bispecific antibodies entering clinical trials, developed by companies like Roche.
- The review covers the principles of CrossMab technology and its application, highlighting two antibodies in advanced stages: faricimab for regulatory review and glofitamab in Phase 3 trials.
$100 - $150
Hourly Rate
Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders.
London, UK
2 hours ago
1 Received
- Recent advancements in treating B-cell lymphoma and chronic lymphocytic leukemia (CLL) have shifted towards targeted therapies, particularly immunotherapeutics.
- These therapies utilize B-cell-associated antigens, such as CD19 and CD20, and include monoclonal antibodies, bispecific antibodies, and CAR-T cell therapy to enhance treatment efficacy.
- Bispecific T-cell engagers (TCEs) show promise, especially anti-CD20xCD3, while antibody-drug conjugates targeting various B-cell antigens demonstrate effectiveness when used with other treatments, warranting further research into their potential to replace traditional chemotherapy.
$100 - $150
Hourly Rate
Glofitamab CD20-TCB bispecific antibody.
London, UK
2 hours ago
1 Received
- Bispecific T-cell recruiting antibodies, like glofitamab, are promising treatments for B-cell malignancies by targeting both T-cells and cancer cells to induce tumor cell death.
- Glofitamab uniquely has a 2:1 configuration that enhances its half-life and binding to CD20, showing strong efficacy in Phase 1 trials with over 50% complete responses in difficult-to-treat B-cell lymphoma patients.
- This review highlights glofitamab's structure, function, safety, and effectiveness data, suggesting it could be a vital option for patients with limited treatment alternatives.
$100 - $150
Hourly Rate
Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma.
London, UK
2 hours ago
1 Received
- - Glofitamab is a new bispecific antibody that targets CD20 on cancerous B-cells and CD3 on T-cells, showing promise as a standalone treatment for patients with relapsed/refractory B-cell non-Hodgkin lymphoma in a phase 1 trial (Study NP30179).
- - The trial involved a pretreatment with obinutuzumab followed by glofitamab infusions, and findings indicated that glofitamab activates T-cells and induces various cytokines, suggesting its effectiveness in killing tumor cells.
- - Biomarker analysis revealed that certain tumor factors, like TP53 signaling, are linked to resistance against glofitamab, indicating that these could serve as potential progn
$100 - $150
Hourly Rate
Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
London, UK
2 hours ago
1 Received
- Despite advancements in non-Hodgkin lymphoma (NHL) treatment, relapsed and refractory cases still pose significant challenges, highlighting the need for better therapies.
- T-cell redirecting immunotherapies, particularly bispecific antibodies (BsAbs), show great promise for NHL by targeting both T-cells and malignant B-cells, with newer agents like odronextamab and mosunetuzumab demonstrating favorable safety and efficacy profiles.
- Ongoing studies aim to address key questions about the optimal use of BsAbs in treatment plans, their potential in newly diagnosed cases, and their effectiveness when combined with other treatments, including CAR T-cell therapy.
$100 - $150
Hourly Rate
Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab.
London, UK
2 hours ago
1 Received
- Researchers developed a new method for selecting a starting dose for the bispecific antibody glofitamab in humans, using data from cynomolgus monkeys to assess pharmacokinetics and pharmacodynamics (PKPD).
- The study focused on the release of cytokines (immune system signaling molecules) and determined that the response to glofitamab differed significantly between monkeys and humans, impacting dose selection.
- A starting dose of 5 µg was chosen for human trials to ensure cytokine release remained below a specific clinical threshold, marking a novel approach in dosage determination for B-cell lymphoma treatment.
$100 - $150
Hourly Rate
Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy.
London, UK
2 hours ago
1 Received
- CAR T-cell therapy is a standard treatment for patients with refractory or relapsed diffuse large B-cell lymphomas (DLBCL), but outcomes for those who relapse after CAR T are poor and options are limited.
- This study explored the effects of the bispecific CD20xCD3 antibody glofitamab on nine patients who had progressive DLBCL after CAR T-cell therapy, using a maximum of 12 cycles following a single obinutuzumab pre-treatment.
- The results showed that glofitamab is well tolerated with a 67% overall response rate, including complete and partial responses, and it may help boost the activity of residual CAR T-cells in the bloodstream.
$100 - $150
Hourly Rate
Immunotherapy in indolent Non-Hodgkin's Lymphoma.
London, UK
2 hours ago
1 Received
- - The treatment options for non-Hodgkin lymphoma (NHL) have improved with the introduction of monoclonal antibody (MAB) therapy, particularly focusing on B cell and T cell subtypes, and categorized into aggressive and indolent forms.
- - Rituximab, an anti-CD20 MAB, revolutionized treatment for indolent B cell NHL, like follicular lymphoma, by directly targeting cancerous B cells and becoming FDA approved in 1997.
- - Despite its effectiveness, challenges such as resistance mechanisms have prompted interest in combining immunotherapy with radio-sensitizing agents, leading to advancements in drugs like 90Y-ibritumomab tiuxetan and ofatumumab
$100 - $150
Hourly Rate
Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.
London, UK
2 hours ago
1 Received
- Diffuse large B-cell lymphoma is a severe type of cancer with varying biological behavior, treated primarily with R-CHOP, which successfully cures over 60% of patients.
- For patients who relapse, high-dose chemotherapy and stem cell transplants are the standard approach, with newer treatments like CD19 CAR T-cells recently approved for certain cases.
- Bispecific antibodies (BsAbs), designed to target CD20 on B cells while engaging T cells, show promising results in clinical trials, offering a favorable safety profile and potential effectiveness even in aggressive lymphomas, with ongoing research to further evaluate their use.
$100 - $150
Hourly Rate
Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma.
London, UK
2 hours ago
1 Received
- Mantle cell lymphoma (MCL) is a rare and aggressive type of B-cell Non-Hodgkin lymphoma that primarily affects men, with most patients experiencing relapses after initial treatments.
- Recent advancements, including the use of CAR T therapy, have improved survival rates, but options for patients who relapse post-CAR T are still limited.
- Two cases of patients who relapsed after CAR T therapy were treated with the bispecific antibody glofitamab, resulting in increased CAR T cells and positive responses, suggesting this therapy could be a promising option for similar cases.
$100 - $150
Hourly Rate
[Current status and future prospects of diffuse large B-cell lymphoma treatment].
London, UK
2 hours ago
1 Received
- R-CHOP therapy, which includes components like rituximab and doxorubicin, has been the go-to treatment for newly diagnosed diffuse large B-cell lymphoma (DLBCL) since the early 2000s.
- New therapies such as polatuzumab vedotin and CAR-T therapy are now available for patients whose DLBCL has relapsed or doesn’t respond to initial treatments.
- Several emerging treatment options, including bispecific antibodies and new drug combinations, are currently being explored to improve outcomes for DLBCL patients in Japan.
$100 - $150
Hourly Rate
Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody.
London, UK
2 hours ago
1 Received
- Glofitamab, tafasitamab, loncastuximab tesirine, polatuzumab, and selinexor are under investigation for treating relapsed-refractory diffuse large B-cell lymphoma (DLBCL), with a focus on overall survival (OS).
- Researchers used AI to reconstruct patient-level data from published survival curves to make cross-trial comparisons for these treatments' efficacy.
- The analysis showed that tafasitamab plus lenalidomide had the best survival outcomes, while glofitamab did not show an overall survival benefit compared to the other treatments, despite its advanced mechanism.
$100 - $150
Hourly Rate
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
London, UK
2 hours ago
1 Received
- Glofitamab, a bispecific antibody, shows promise for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with 39% of patients achieving a complete response after treatment.
- In a phase 2 trial involving patients who had undergone at least two previous therapies, the medication was administered following obinutuzumab pretreatment to reduce side effects.
- Although the treatment was effective, 78% of complete responses were ongoing at 12 months, but 62% of patients experienced significant adverse events, primarily cytokine release syndrome.
$100 - $150
Hourly Rate